Benzimidazole compound and medical use thereof

1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein

R 1a , R 1b , R 1c , and R 1d are each independently hydrogen, halogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, C 3-7 cycloalkyl, C 3-7 cycloalkoxy, C 3-7 cycloalkylamino, C 6-10 aryl, C 6-10 aryloxy, 5- to 12-membered heteroaryl, or 5- to 12-membered heteroaryloxy;

wherein each alkyl moiety of the alkyl, alkoxy and alkylamino of R 1a , R 1b ,R 1c ,and R 1d is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, hydroxyl, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 3-7 cycloalkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, C 3-7 cycloalkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, and 3- to 7-membered non-aromatic heterocyclyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B;

each cycloalkyl moiety of the cycloalkyl, the cycloalkoxy, and the cycloalkylamino of R 1a , R 1b , R 1c ,and R 1d is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, hydroxyl, C 1-4 alkyl optionally-substituted with 1 to 3 substituents selected independently from Substituent-group A, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents selected independently from Substituent-group A, C 3-7 cycloalkyl optionally-substituted with 1 to 3 substituents selected independently from Substituent-group B, and C 3-7 cycloalkoxy optionally-substituted with 1 to 3 substituents selected independently from Substituent-group B); and

each aryl moiety of the aryl and the aryloxy and each heteroaryl moiety of the heteroaryl and the heteroaryloxy of R 1a , R 1b , R 1c , and R 1d is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, C 1-4 alkyl optionally-substituted with 1 to 3 substituents selected independently from Substituent-group A, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents selected independently from Substituent-group A, C 3-7 cycloalkyl optionally-substituted with 1 to 3 substituents selected independently from Substituent-group B, C 3-7 cycloalkoxy optionally-substituted with 1 to 3 substituents selected independently from Substituent-group B, 3- to 7-membered non-aromatic heterocyclyl optionally-substituted with 1 to 3 substituents selected independently from Substituent-group B, C 1-4 alkylthio optionally-substituted with 1 to 3 substituents selected independently from Substituent-group A, and C 1-4 alkylsulfonyl optionally-substituted with 1 to 3 substituents selected independently from Substituent-group A;

provided that at least one of R 1a , R 1b , R 1c and R 1d is C 6-10 aryl, C 6-10 aryloxy, 5- to 12-membered heteroaryl or 5- to 12-membered heteroaryloxy;

R 2 and R 3 are each independently hydrogen, C 1-6 alkyl which is optionally substituted with 1 to 5 substituents independently selected from the group consisting of cyano, halogen, hydroxyl, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents selected independently from Substituent-group A, C 3-7 cycloalkyl optionally-substituted with 1 to 3 substituents selected independently from Substituent-group B, and C 3-7 cycloalkoxy optionally-substituted with 1 to 3 substituents selected independently from Substituent-group B, or C 3-10 cycloalkyl;

R 4 is hydrogen, C 1-6 alkyl which is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 3-7 cycloalkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, C 3-7 cycloalkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, and 3- to 7-membered non-aromatic heterocyclyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, or C 3-7 cycloalkyl which optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, C 1-4 alkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 3-7 cycloalkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, and C 3-7 cycloalkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B;

m is 1, 2 or 3;

L is CR 7 R 8 , provided that when m is 2 or 3, each CR 7 R 8 are independently the same or different;

R 7 and R 8 are each independently hydrogen, hydroxyl, C 1-4 alkyl, C 1-4 alkoxy, C 3-7 cycloalkyl, or C 3-7 cycloalkoxy,

wherein each alkyl moiety of the alkyl and the alkoxy of R 7 and R 8 is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 3-7 cycloalkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, C 3-7 cycloalkoxy optionally-substituted with 1 to 3substituents independently selected from Substituent-group B, and 3- to 7-membered non-aromatic heterocyclyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B;

wherein each cycloalkyl moiety of the cycloalkyl and the cycloalkoxy of R 7 and R 8 is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, C 1-4 alkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 3-7 cycloalkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, and C 3-7 cycloalkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B; or

R 2 and R 3 may be combined together with the carbon atom to which they are attached to form the following group of formula (II) with —OR 4 :

wherein:

e and f are each independently 1, 2 or 3;

V is single bond or oxygen atom;

R 5a , R 5b , R 5c ,and R 5d are each independently hydrogen, halogen, hydroxyl, C 1-4 alkyl, or C 1-4 alkoxy;

wherein each alkyl moiety of the alkyl and the alkoxy of R 5a , R 5b , R 5c , and R 5d is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 3-7 cycloalkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, C 3-7 cycloalkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, and 3- to 7-membered non-aromatic heterocyclyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B; or

in R 2 , R 3 , —OR 4 and CR 7 R 8 of L,

R 2 and R 7 may be combined together with the carbon atom to which they are attached to form the following group of formula (IV) with R 3 , —OR 4 and R 8 :

wherein:

m 1 is 0 or 1; and

m 2 is 0 or 1 and j is 1, 2, 3 or 4 when m 1 is 1; or

m 2 is 0, 1 or 2 and j is 1, 2, 3 or 4 when m 1 is 0;

R 9a , R 9b , R 9c , and R 9d are each independently hydrogen, halogen, hydroxyl, C 1-4 alkyl, or C 1-4 alkoxy;

wherein each alkyl moiety of the alkyl and the alkoxy of R 9a , R 9b , R 9c , and R 9d is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 3-7 cycloalkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, C 3-7 cycloalkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, and 3- to 7-membered non-aromatic heterocyclyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B; or

R 3 and —OR 4 may be combined together with the carbon atom to which they are attached to form the following group of formula (III) with R 2 :

wherein:

h is 1, 2, 3, or 4; and

R 6a , R 6b , and R 6c are each independently hydrogen, halogen, hydroxyl, C 1-4 alkyl, or C 1-4 alkoxy;

wherein each alkyl moiety of the alkyl and the alkoxy of R 6a , R 6b , and R 6c is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 3-7 cycloalkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, C 3-7 cycloalkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, and 3- to 7-membered non-aromatic heterocyclyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B;

provided that all of R 2 , R 3 and —OR 4 are not combined together to form a ring;

each Substituent-group A is independently halogen, hydroxyl, C 1-4 alkoxy, C 3-7 cycloalkyl, or C 3-7 cycloalkoxy; and

each Substituent-group B is independently halogen, hydroxyl, C 1-4 alkyl, C 1-4 alkoxy, C 3-7 cycloalkyl, or C 3-7 cycloalkoxy;

provided that the following compounds are excluded from the compounds of Formula (I):

6-[6-chloro-2-(morpholin-4-yl)pyrimidin-4-yl]-1-(2-methoxyethyl)-1H-benzimidazole,

2-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-benzimidazol-1-yl]ethanol,

2-{5-[5-(tetrahydrofuran-3-yl)-4H-1,2,4-triazol-3-yl]-1H-benzimidazol-1-yl}ethanol,

2-{5-[3-(2-methoxyethyl)-1-(2,2,2-trifluoroethyl)-1H-1,2,4-triazol-5-yl]-1H-benzimidazol-1-yl }ethanol,

2-{5-[3-methyl-1-(1-methylpiperidin-4-yl)-1H-1,2,4-triazol-5-yl]-1H-benzimidazol-1-yl}ethanol,

2-butyl-6-[1-(2-hydroxyethyl)-1H-benzimidazol-6-yl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one,

6-[1-(2-hydroxyethyl)-1H-benzimidazol-6-yl]-2-(3-methylbutyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one,

2-{5-[1-(2-hydroxyethyl)-1H-benzimidazol-5-yl]-1H-1,2,4-triazol-1-yl}ethanol,

6-(2-chlorophenyl)-1-(2-hydroxyethyl)-1H-benzimidazole-7-carbonitrile,

2-chloro-6-{7-fluoro-1-[(1S,3S)-3-methoxycyclohexyl]-1H-benzimidazol-5-yl}-9-(tetrahydro-2H-pyran-2-yl)-9H-purine, and

2-{5-[2-(tetrahydrofuran-3-yl)-1H-imidazol-1-yl]-1H-benzimidazol-1-yl}ethanol.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein:

R 1a , R 1b ,R 1c ,and R 1d are each independently hydrogen, halogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 6-10 aryl, C 6-10 aryloxy, 5- to 12-membered heteroaryl, or 5- to 12-membered heteroaryloxy;

wherein each alkyl moiety of the alkyl and the alkoxy of R 1a , R 1b ,R 1c , and R 1d is optionally substituted with 1 to 3 independently selected halogens;

wherein each aryl moiety of the aryl and the aryloxy and each heteroaryl moiety of the heteroaryl and the heteroaryloxy of R 1a ,R 1b ,R 1c , and R 1d is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C 1-4 alkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, and C 1-4 alkylsulfonyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 1a ,R 1b ,R 1c ,and R 1d are each independently hydrogen, C 6-10 aryl, C 6-10 aryloxy, 5- to 12-membered heteroaryl, or 5- to 12-membered heteroaryloxy, wherein each aryl moiety of the aryl and the aryloxy and each heteroaryl moiety of the heteroaryl and the heteroaryloxy of R 1a , R 1b , R 1c , and R 1d is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen and C 1-4 alkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1a and R 1d are each hydrogen.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 2 and R 3 are each independently hydrogen or C 1-6 alkyl which may be independently substituted with 1 to 5 substituents independently selected from the group consisting of cyano, halogen, hydroxyl, and C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, provided that both of R 2 and R 3 are not hydrogen; or

R 2 and R 3 may be combined together with the carbon atom to which they are attached to form the following group of formula (IIa) with —OR 4 :

wherein:

e and f are each independently 1 or 2;

R 5a , R 5b , R 5c , and R 5d are each independently hydrogen or halogen; or

in R 2 , R 3 , —OR 4 and CR 7 R 8 in L:

R 2 and R 7 may be combined together with the carbon atom to which they are attached to form the following group of formula (IVa) with R 3 , —OR 4 , and R 8 :

wherein

m 1 is 0;

m 2 is 1 or 2;

j is 1, 2 or 3;

R 3 is hydrogen or C 1-6 alkyl which may be independently substituted with 1 to 5 substituents independently selected from the group consisting of cyano, halogen, hydroxyl, and C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A;

and

R 9a , R 9b , R 9c , and R 9d are each independently hydrogen or halogen.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 2 and R 3 are each independently C 1-6 alkyl optionally-substituted 1 to 5 independently selected halogens; or

R 2 and R 3 may be combined together with the carbon atom to which they are attached to form the following group of formula (IIb) with —OR 4 :

wherein:

e and f are each independently 1 or 2; and

R 5a , R 5b , R 5c , and R 5d are each independently hydrogen or halogen; or

in R 2 , R 3 , —OR 4 and CR 7 R 8 in L:

R 2 and R 7 may be combined together with the carbon atom to which they are attached to form the following group of formula (IVa) with R 3 , —OR 4 and R 8 :

wherein:

m 1 is 0;

m 2 is 1 or 2;

j is 1, 2 or 3;

R 4 is hydrogen; and

R 9a , R 9b , R 9c , and R 9d are each independently hydrogen or halogen.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 2 and R 3 are each independently hydrogen or C 1-6 alkyl optionally-substituted with 1 to 5 independently selected halogens.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 4 is hydrogen, C 1-4 alkyl optionally-substituted with 1 to 3 independently selected halogens, or C 3-7 cycloalkyl which is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, and C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A; or

R 3 and —OR 4 may be combined together with the carbon atom to which they are attached to form the following group of formula (IIIa) with R 2 :

wherein:

h is 1, 2, or 3;

R 6a ,R 6b , and R 6c are each independently hydrogen, halogen, or C 1-4 alkyl optionally-substituted with 1 to 3 independently selected halogens.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 4 is hydrogen, C 1-4 alkyl optionally-substituted with 1 to 3 independently selected halogens, or C 3-7 cycloalkyl which is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, and C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is hydrogen.

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 7 and R 8 are each independently hydrogen or C 1-4 alkyl which is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 3-7 cycloalkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, C 3-7 cycloalkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, and 3- to 7-membered non-aromatic heterocyclyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group B, and

m is 1 or 2.

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 and R 8 are each hydrogen, and m is 1.

13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 1b or R 1c is C 6-10 aryl, C 6-10 aryloxy, 5- to 12-membered heteroaryl, or 5- to 12-membered heteroaryloxy;

wherein each aryl moiety of the aryl and the aryloxy and each heteroaryl moiety of the heteroaryl and the heteroaryloxy of R 1b and R 1c is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C 1-4 alkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, and C 1-4 alkylsulfonyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A.

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 1b is C 6-10 aryl, C 6-10 aryloxy, 5- to 12-membered heteroaryl, or 5 - to 12-membered heteroaryloxy;

wherein each aryl moiety of the aryl and the aryloxy and each heteroaryl moiety of the heteroaryl and the heteroaryloxy of R 1b is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C 1-4 alkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, and C 1-4 alkylsulfonyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A.

15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 1c is C 6-10 aryl, C 6-10 aryloxy, 5- to 12-membered heteroaryl, or 5- to 12-membered heteroaryloxy;

wherein each aryl moiety of the aryl and the aryloxy and each heteroaryl moiety of the heteroaryl and the heteroaryloxy of R 1c is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C 1-4 alkyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A, and C 1-4 alkylsulfonyl optionally-substituted with 1 to 3 substituents independently selected from Substituent-group A.

16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is selected from the group of compounds consisting of:

1-[6-(4-fluorophenoxy)-1H-benzimidazol-1-yl]-2-methylpropan-2-ol,

6-(4-fluorophenoxy)-1-(tetrahydrofuran-2-ylmethyl)-1H-benzimidazole,

1-(tetrahydrofuran-2-ylmethyl)-6-[4-(trifluoromethyl)phenyl]-1H-benzimidazole,

2-methyl-1-{6-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-1-yl }propan-2-ol,

1-[2-(cyclopentyloxy)ethyl]-6-[4-(trifluoromethyl)phenyl]-1H-benzimidazole,

2-methyl-1-{6-[5-(trifluoromethyl)pyridin-2-yl]-1H-benzimidazol-1-yl}propan-2-ol,

1-[2-(cyclopentyloxy)ethyl]-6-[5-(trifluoromethyl)pyridin-2-yl]-1H-benzimidazole,

2-methyl-1-[6-(4-methylphenoxy)-1H-benzimidazol-1-yl]propan-2-ol,

2-methyl-1-{6-[4-(trifluoromethyl)phenoxy]-1H-benzimidazol-1-yl}propan-2-ol,

1-[6-(4-chlorophenoxy)-1H-benzimidazol-1-yl]-2-methylpropan-2-ol,

2-methyl-1-{6-[4-(trifluoromethoxy)phenoxy]-1H-benzimidazol-1-yl}propan-2-ol,

2-methyl-1-{6-[(6-methylpyridin-3-yl)oxy]-1H-benzimidazol-1-yl}propan-2-ol,

2-methyl-1-(6-{[6-(trifluoromethyl)pyridin-3-yl]oxy}-1H-benzimidazol-1-yl)propan-2-ol,

2-methyl-1-(6-{[5-(trifluoromethyl)pyridin-2-yl]oxy}-1H-benzimidazol-1-yl)propan-2-ol,

2-methyl-1-(5-{[5-(trifluoromethyl)pyrazin-2-yl]oxy}-1H-benzimidazol-1-yl)propan-2-ol,

2-methyl-1-(5-{[5-(trifluoromethyl)pyrimidin-2-yl]oxy}-1H-benzimidazol-1-yl)propan-2-ol,

1-(5-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]oxy}-1H-benzimidazol-1-yl)-2-methylpropan-2-ol,

1-{5-[(5-chloro-3-fluoropyridin-2-yl)oxy]-1H-benzimidazol-1-yl}-2-methylpropan-2-ol,

3-[(6-{[5-(trifluoromethyl)pyridin-2-yl]oxy}-1H-benzimidazol-1-yl)methyl]oxetan-3-ol,

1-[(6-{[5-(trifluoromethyl)pyridin-2-yl]oxy}-1H-benzimidazol-1-yl)methyl]cyclobutanol,

2-methyl-4-(6-{[5-(trifluoromethyl)pyridin-2-yl]oxy}-1H-benzimidazol-1-yl)butan-2-ol,

2-methyl-1-(6-{[5-(2,2,2-trifluoroethyl)pyridin-2-yl]oxy}-1H-benzimidazol-1-yl)propan-2-ol,

3-({6-[4-(trifluoromethyl)phenoxy]-1H-benzimidazol-1-yl}methy)oxetan-3-ol,

3-({6-[4-(trifluoromethoxy)phenoxy]-1H-benzimidazol-1-yl}methyl)oxetan-3-ol,

4-[6-(4-chlorophenoxy)-1H-benzimidazol-1-yl]-2-methylbutan-2-ol,

3-{[6-(2-chloro-4-fluorophenoxy)-1H-benzimidazol-1-yl]methyl}oxetan-3-ol,

cis-4-(6-{[5-(trifluoromethyl)pyridin-2-yl]oxy}-1H-benzimidazol-1-yl)cyclohexanol,

1-{6-[2-fluoro-4-(trifluoromethyl)phenyl]-1H-benzimidazol-1-yl}-2-methylpropan-2-ol,

1-[6-(4-chloro-2-fluorophenyl)-1H-benzimidazol-1-yl]-2-methylpropan-2-ol,

3-({6-[2-methoxy-4-(trifluoromethyl)phenyl]-1H-benzimidazol-1-yl}methyl)oxetan-3-ol,

4-{6-[2-methoxy-4-(trifluoromethyl)phenyl]-1H-benzimidazol-1-yl }-2-methylbutan-2-ol,

1-{5-[2-methoxy-4-(trifluoromethyl)phenyl]-1H-benzimidazol-1-yl}-2-methylpropan-2-ol,

2-methyl-1-{5-[4-(trifluoromethoxy)phenyl]-1H-benzimidazol-1-yl}propan-2-ol,

1-{5-[2-fluoro-4-(trifluoromethyl)phenyl]-1H-benzimidazol-1-yl}-2-methylpropan-2-ol,

3-({5-[2-methoxy-4-(trifluoromethyl)phenyl]-1H-benzimidazol-1-yl}methyl)oxetan-3-ol, and

(3S)-2-methyl-3-(6-{[5-(trifluoromethyl)pyridin-2-yl]oxy}-1H-benzimidazol-1-yl)butan-2-ol.

17. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is selected from the group of compounds consisting of:

1-[6-(4-fluorophenoxy)-1H-benzimidazol-1-yl]-2-methylpropan-2-ol,

2-methyl-1-{6-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-1-yl}propan-2-ol,

2-methyl-1-{6-[5-(trifluoromethyl)pyridin-2-yl]-1H-benzimidazol-1-yl}propan-2-ol,

2-methyl-1-{6-[4-(trifluoromethyl)phenoxy]-1H-benzimidazol-1-yl}propan-2-ol,

1-[6-(4-chlorophenoxy)-1H-benzimidazol-1-yl]-2-methylpropan-2-ol,

2-methyl-1-{6-[4-(trifluoromethoxy)phenoxy]-1H-benzimidazol-1-yl}propan-2-ol,

2-methyl-1-{6-[(6-methylpyridin-3-yl)oxy]-1H-benzimidazol-1-yl}propan-2-ol,

2-methyl-1-(6-{[5-(trifluoromethyl)pyridin-2-yl]oxy}-1H-benzimidazol-1-yl)propan-2-ol,

2-methyl-1-(5-{[5-(trifluoromethyl)pyrazin-2-yl]oxy}-1H-benzimidazol-1-yl)propan-2-ol,

1-(5-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]oxy}-1H-benzimidazol-1-yl)-2-methylpropan-2-ol,

2-methyl-4-(6-{[5-(trifluoromethyl)pyridin-2-yl]oxy}-1H-benzimidazol-1-yl)butan-2-ol,

2-methyl-1-(6-{[5-(2,2,2-trifluoroethyl)pyridin-2-yl]oxy}-1H-benzimidazol-1-yl)propan-2-ol,

3-({6-[4-(trifluoromethoxy)phenoxy]-1H-benzimidazol-1-yl}methyl)oxetan-3-ol,

4-[6-(4-chlorophenoxy)-1H-benzimidazol-1-yl]-2-methylbutan-2-ol,

cis-4-(6-{[5-(trifluoromethyl)pyridin-2-yl]oxy}-1H-benzimidazol-1-yl)cyclohexanol,

1-{6-[2-fluoro-4-(trifluoromethyl)phenyl]-1H-benzimidazol-1-yl}-2-methylpropan-2-ol,

3-({6-[2-methoxy-4-(trifluoromethyl)phenyl]-1H-benzimidazol-1-yl}methyl)oxetan-3-ol,

3-({5-[2-methoxy-4-(trifluoromethyl)phenyl]-1H-benzimidazol-1-yl}methyl)oxetan-3-ol, and

(3S)-2-methyl-3-(6-{[5-(trifluoromethyl)pyridin-2-yl]oxy}-1H-benzimidazol-1-yl)butan-2-ol.

18. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive agent.

19. A method of treating a disease involving NAV1.7 (SCN9A) in a subject, comprising administering to the subject the compound of claim 1 , or a pharmaceutically acceptable salt thereof, as an active ingredient.

20. A pharmaceutical combination comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one drug selected from the group consisting of an antiepileptic agent, an antidepressive agent, a narcotic analgesic, an anti-inflammatory agent, a reductase inhibitor, and a prostaglandin derivative drug.

21. A method of treating neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, or multiple sclerosis in a mammal in need thereof, which comprises administering a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, to the mammal.

22. The method of claim 21 , further comprising administering a therapeutically effective amount of at least one drug selected from the group consisting of an antiepileptic agent, an antidepressive agent, a narcotic analgesic, an anti-inflammatory agent, a reductase inhibitor, and a prostaglandin derivative drug.

23. The method of claim 21 , further comprising administering a therapeutically effective amount of a narcotic analgesic.

24. The method of claim 23 , wherein the narcotic analgesic is morphine, oxycodone, or tramadol.

25. A pharmaceutical combination comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a narcotic analgesic.

26. The pharmaceutical combination of claim 25 , wherein the narcotic analgesic is morphine, oxycodone, or tramadol.

27. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1a and R 1d are hydrogen,

at least one of R 1b and R 1c is C 6-10 aryl, C 6-10 aryloxy, 5- to 12-membered heteroaryl, or 5- to 12-membered heteroaryloxy, wherein each aryl moiety of the aryl and the aryloxy and each heteroaryl moiety of the heteroaryl and the heteroaryloxy may be independently substituted with 1 to 3 substituents selected independently from the group consisting of halogen and C 1-4 alkyl optionally-substituted with 1 to 3 substituents selected independently from Substituent-group A,

R 2 and R 3 are independently C 1-6 alkyl optionally-substituted with the same or different and 1 to 5 halogens, or

R 2 and R 3 may be combined together with the carbon atom to which they are attached to form the following group of formula (Ilb) with —OR 4

in formula (IIb),

e and f are independently 1 or 2,

R 4 is hydrogen, C 1-6 alkyl which may be substituted with 1 to 3 substituents selected independently from the group consisting of halogen, hydroxyl, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents selected independently from Substituent-group A, C 3-7 cycloalkyl optionally-substituted with 1 to 3 substituents selected independently from Substituent-group B, C 3-7 cycloalkoxy optionally-substituted with 1 to 3 substituents selected independently from Substituent-group B, and 3- to 7-membered non-aromatic heterocyclyl optionally-substituted with 1 to 3 substituents selected independently from Substituent-group B, or C 3-7 cycloalkyl which may be independently substituted with 1 to 3 substituents selected independently from the group consisting of halogen, hydroxyl, C 1-4 alkyl optionally-substituted with 1 to 3 substituents selected independently from Substituent-group A, C 1-4 alkoxy optionally-substituted with 1 to 3 substituents selected independently from Substituent-group A, C3-7cycloalkyl optionally-substituted with 1 to 3 substituents selected independently from Substituent-group B, and C 3-7 cycloalkoxy optionally-substituted with 1 to 3 substituents selected independently from Substituent-group B,

V is single bond or oxygen atom,

R 5a , R 5b , R 5c , and R 5d are independently hydrogen or halogen, or

in R 2 , R 3 , —OR 4 and CR 7 R 8 in L,

R 2 and R 7 may be combined together with the carbon atom to which they are attached to form the following group of formula (IVa) with R 3 , —OR 4 and R 8

in formula (IVa),

m 1 is 0,

m 2 is 1 or 2,

j is 1 or 2,

R 3 is hydrogen or C 1-4 alkyl,

R 4 is hydrogen,

R 8 is hydrogen or C 1-4 alkyl,

L is CR 7 R 8 , provided that when m is 2, each CR 7 R 8 are independently the same or different,

R 9a , R 9b , R 9c , and R 9d are independently hydrogen or halogen,

R 4 is hydrogen, C 1-4 alkyl optionally-substituted with the same or different and 1 to 3 halogens, or C 3-7 cycloalkyl optionally-substituted with the same or different and 1 to 3 halogens, or

R 3 and —OR 4 may be combined together with the carbon atom to which they are attached to form the following group of formula (IIIa) with R 2

in formula (IIIa),

h is 1, 2 or 3,

R 2 is hydrogen or C 1-4 alkyl optionally-substituted with the same or different and 1 to 3 halogens,

R 6a , R 6b , and R 6c are independently hydrogen, halogen, or C 1-4 alkyl optionally-substituted with the same or different and 1 to 3 halogens,

m is 1 or 2,

L is CR 7 R 8 , provided that when m is 2, each CR 7 R 8 are independently the same or different,

R 7 and R 8 are independently hydrogen or C 1-4 alkyl optionally-substituted with the same or different and 1 to 3 halogens.